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Accepted 23 March 2019Objective: Compare bleeding patterns for levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine system (IUS)
products using the World Health Organization Belsey deﬁnitions.
Study design:We extracted available data on bleeding patterns from published sources. Lower dose products had
published data at 1 and 3 years; the 52 mg IUS had available data for 1, 2 and 3 years for amenorrhea and 1 and
2 years for other bleeding patterns. We interpolated 2-year data for the lower dose products based on 1- and
3-year data and compared bleeding pattern rates using Fisher exact testing.
Results: The studies evaluated bleeding patterns in 1700, 1566 and 1531womenusing levonorgestrel 52mg, 19.5
mg and 13.5mg products, respectively. Amenorrhea rates were greater by 180 days after insertion for 52mg IUS
users (11%) as compared to 19.5 mg (5%, pb.0001) and 13.5 mg (3%, pb.0001). Infrequent bleeding rates were
higher for 52 mg users by the end of year 1 (31%) compared to 19.5 mg (26%, p=.01) and 13.5 mg
(20%, pb.0001). Irregular bleeding rates were higher with the lower dose products by 90 days after insertion
with continued lower rates at the end of year 1 for 52 mg users (6%) compared 19.5 mg (17%, pb.0001) and
13.5 mg (23%, pb.0001). Frequent and prolonged bleeding patterns were similar over the ﬁrst 2 years for all
products, although the rates were statistically higher for levonorgestrel 13.5 mg IUS users compared to 19.5
mg and 52 mg IUS users (p≤.03 for all time points after 90-days post-insertion).
Conclusions: Levonorgestrel 52 mg IUS users have more amenorrhea and infrequent bleeding and less irregular
bleeding compared to women using lower dose levonorgestrel IUS products.
Implications Statement: All women considering levonorgestrel IUS placement should receive counseling on
the differences in bleeding patterns related to the various available doses. Women who are interested in
maximizing the likelihood of favorable bleeding should consider a levonorgestrel 52 mg IUS over the
lower dose alternatives.
© 2019 Elsevier Inc. All rights reserved.Keywords:
Amenorrhea
Bleeding
Intrauterine device
Intrauterine system
Levonorgestrel
Spotting1. Introduction
Standardized reporting of bleeding with contraceptive use has been
endorsed for decades [1,2]. However, research studies and pharmaceu-
tical company clinical trial reports submitted for agency approval con-
tinue to use a variety of methods for reporting bleeding patterns [3].
The World Health Organization (WHO) recommends using the Belsey
criteria when reporting hormonal contraception bleeding patterns [1]
(Table 1).
We see this reporting variation in the prescribing information for
the three different doses of levonorgestrel intrauterine system (IUS)
products (52 mg, 19.5 mg, and 13.5 mg) in which data are provided in
different ways, even among dose-equivalent products [4–7]. As such,
clinically relevant differences in bleeding patterns are difﬁcult to distill
for both clinicians and patients.).A signiﬁcant advantage of drug approval studies is the large size and
detailed collection of bleeding data from the study population. In this
report, we use published data from these contemporary studies of the
available levonorgestrel IUS products to compare bleeding patterns
using the WHO Belsey criteria.
2. Materials and methods
We assessed bleeding patterns using the WHO Belsey criteria
(Table 1) over 90-day intervals (reference periods) [1] through
3 years for amenorrhea and two years for other bleeding descriptors
for the three marketed levonorgestrel IUS dose products. We com-
pared the patterns using published or publicly available data for
the levonorgestrel 52 mg, [8] 19.5 mg [4,9] and 13.5 mg [7,10] IUS
products. Although two levonorgestrel 52 mg IUS products are FDA
approved in the United States, published data using the WHO Belsey
criteria are available for only one (Liletta®, Medicines360, San
Francisco, CA and Allergan, Irvine, CA). The available data for the
Table 1
World Health Organization Belsey deﬁnitions of bleeding patterns with contraceptive
use [1].
Bleeding/Spotting Episode One or more consecutive days during which
blood loss (bleeding or spotting) has been
entered on the calendar record; each episode
being bounded by bleeding/spotting-free days
Amenorrhea No bleeding or spotting during a 90-day
reference period
Prolonged bleeding Bleeding/spotting episodes lasting more than
14 days during a 90-day reference period
Frequent bleeding More than ﬁve bleeding/spotting episodes
during a 90-day reference period
Infrequent bleeding One or two bleeding/spotting episodes during
a 90-day reference period
Irregular bleeding Three to ﬁve bleeding/spotting episodes and
less than three bleeding/spotting-free
intervals of 14 days or more during a 90-day
reference period
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ﬁrst and second 90-day reference periods and at 1 and 2 years as
well as amenorrhea rates at 3 years. For both lower dose products,
bleeding pattern descriptions are reported for the ﬁrst and second
90-day reference periods and at 1 and 3 years; thus, we performed
a linear interpolation of the data to derive 2-year estimates for com-
parisons to the levonorgestrel 52 mg IUS data. Because we estimated
2-year values for the 19.5 mg and 13.5 mg products and did not have
actual numbers of subjects for the outcomes at 2 years, we did not
perform statistical comparisons for this time point. We used Fisher's
exact testing for comparisons of proportions with p-values≤0.05
considered signiﬁcant.
3. Results
Table 2 compares amenorrhea rates between users of the levonor-
gestrel 52 mg, 19.5 mg and 13.5 mg IUS. Amenorrhea was uncommon
in the ﬁrst 90 days for all 3 IUS doses and increased over time. During
the second 90-day reference period, amenorrhea rates in levonorgestrel
52mg users (11%) were higher than the rates in levonorgestrel 19.5 mg
(5%, pb.0001) and13.5mg IUSusers (3%, pb.0001); these differences con-
tinued through 3 years at which time amenorrhea was approximately
two-times and three-times higher for levonorgestrel 52 mg users com-
pared to 19.5 mg and 13.5 mg users, respectively. Amenorrhea rates for
women using the levonorgestrel 19.5 mg IUS were also signiﬁcantly
higher than the lower dose 13.5 mg product starting in the second
90-day reference period.
Table 3 compares infrequent, frequent, prolonged, and irregular
bleeding pattern rates reported for levonorgestrel 52 mg, 19.5 mg andTable 2
Amenorrhea rate over 3 years for women using levonorgestrel 52 mg, 19.5 mg and
13.5 mg IUS.
Levonorgestrel IUS 1st 90 2nd 90 End of End of
Dose Days Days Year 1 Year 3
52 mg [8] n=1700 n=1621 n=1448 n=935
7 (0.4%) 183 (11.3%) 269 (18.6%) 340 (36.4%)
19.5 mg [4,9] n=1566 n=1511 n=1371 n=975
3 (0.2%) 80 (5.3%) 168 (12.3%) 194 (19.9%)
13.5 mg [7,10] n=1531 n=1475 n=1329 n=903
5 (0.3%) 44 (3.0%) 83 (6.2%) 105 (11.6%)
p-values
52 mg vs. 19.5 mg .35 b.0001 b.0001 b.0001
52 mg vs. 13.5 mg .78 b.0001 b.0001 b.0001
19.5 mg vs. 13.5 mg .50 b.001 b.0001 b.0001
Amenorrhea deﬁned as no bleeding or spotting during the preceding 90 days.
IUS = Intrauterine System.13.5mg IUS users. Infrequent bleedingwas similar for all 3 products ini-
tially but then increasedmore quickly forwomenusing a levonorgestrel
52 mg IUS. Frequent and prolonged bleeding were uncommon patterns
for users of all three IUS doses by the end of year 1. Irregular bleeding
was also similar for all three products in the ﬁrst 90 days of use,
at around 40% of women. Irregular bleeding rates declined for women
using all three IUS doses; however, fewer 52 mg device users reported
irregular bleeding at 1 year (6% compared to 17% in 19.5 mg [pb.001]
and 23% in 13.5 mg [pb.001] IUS users). Supplemental color ﬁgures
depicting the outcomes in Tables 1 and 2 are available in an
online appendix.
4. Discussion
Bleeding pattern differences between the various doses of levonor-
gestrel over two years of use occur primarily in amenorrhea, infrequent
bleeding and irregular bleeding rates. Women using lower dose
levonorgestrel IUS products had lower rates of amenorrhea and infre-
quent bleeding and had higher rates of irregular bleeding as compared
to women using the 52 mg IUS; rates of frequent and prolonged bleed-
ing were similar for all three doses. None of the products reported a
“regular” cyclic bleeding rate.
Women using any dose levonorgestrel IUS had very similar frequent
and prolonged bleeding pattern rates over the ﬁrst 2 years. For all three
products, frequent bleeding rates decreased quickly to a low rate of ap-
proximately 4–8% by the end of 1 year of use. Prolonged bleeding rates
were slightly higher for levonorgestrel 13.5 mg IUS users at one year
than 19.5 mg or 52 mg IUS users.
A limitation of these comparisons is that the data were gathered
from independent studies with different populations. The lower dose
levonorgestrel IUS studies included a mix of women from 11 countries
in North, Central and South America and Europe whereas the 52 mg
IUS study was performed exclusively in the United States [11,12].
Women in these studies also had different rates of nulliparity and
mean BMI; the levonorgestrel 52 mg IUS study included more nullipa-
rous and obese women [12]. Although variations in characteristics
of the study populations could account for some bleeding pattern
differences, analyses of the levonorgestrel 52 mg IUS data shows no
difference in bleeding patterns based on parity or BMI [8]. Thus, the
likelihood that these differences are impacting the outcomes is low.
An additional limitation is the interpolation of the 2-year data for the
lower dose levonorgestrel IUS products, which is why we did not
perform statistical evaluation of any differences at year 2. Whereas the
overall comparison of outcomes is valid to understand general similari-
ties and differences, a randomized study would be required for a more
precise comparison.
The levonorgestrel 19.5 mg and 13.5 mg products had available
diary data through 3 years [12]. We limited the comparisons of
prolonged, frequent, infrequent and irregular bleeding to two years
because the levonorgestrel 52 mg IUS studies only used daily diaries
for the ﬁrst two years after which investigators obtained bleeding
information by interview [8]. The LNG 52 mg IUS data uses the inter-
view information to provide amenorrhea rates at 3 yearswhich allowed
an amenorrhea comparison after two years.
When considering bleeding patterns with progestin-only methods,
those that are related to a decrease in ﬂow (amenorrhea, infrequent
bleeding) are often considered favorable and those related to increased
or unpredictable ﬂow are often considered unfavorable (frequent,
prolonged and irregular bleeding) [13]. The differences described in
this analysis of published bleeding patterns for the three available
doses of levonorgestrel IUS products, all using the same standard
criteria, show that the 52 mg product has signiﬁcantly more favorable
and less unfavorable bleeding patterns across the ﬁrst few years of
use. Whereas a randomized trial would be the most ideal manner to
compare these outcomes, our ﬁndings summarize and compare the
best information available to inform clinicians and patients given that
Table 3
Infrequent, frequent, prolonged, and irregular bleeding rates over 2 years for women using levonorgestrel 52 mg, 19.5 mg and 13.5 mg IUS.
Levonorgestrel IUS 1st 90 2nd 90 End of End of
Dose Days Days Year 1 Year 2
A. Infrequent bleeding rates
52 mg [8] n=1700 n=1621 n=1448 n=1178
230 (13.5%) 407 (25.1%) 443 (30.6%) 356 (30.2%)
19.5 mg [4,9] n=1566 n=1511 n=1371
150 (9.6%) 307 (20.3%) 360 (26.3%) 26%*
13.5 mg [7,10] n=1531 n=1475 n=1329
129 (8.4%) 282 (19.1%) 271 (20.4%) 21%*
p-values
52 mg vs. 19.5 mg b.001 .002 .01
52 mg vs. 13.5 mg b.0001 b.0001 b.0001
19.5 mg vs. 13.5 mg .29 .43 b.001
B. Frequent bleeding rates
52 mg [8] n=1700 n=1621 n=1448 n=1178
448 (26.4%) 152 (9.4%) 76 (5.2%) 42 (3.6%)
19.5 mg [4,9] n=1566 n=1511 n=1371
391 (25.0%) 147 (9.7%) 58 (4.2%) 3%*
13.5 mg [7,10] n=1531 n=1475 n=1329
468 (30.6%) 180 (12.2%) 100 (7.5%) 6%*
p-values
52 mg vs. 19.5 mg .38 .76 .22
52 mg vs. 13.5 mg .009 .01 .02
19.5 mg vs. 13.5 mg b.001 .03 b.001
C. Prolonged bleeding rates
52 mg [8] n=1700 n=1621 n=1448 n=1178
858 (50.5%) 157 (9.7%) 72 (5.0%) 22 (1.9%)
19.5 mg [4,9] n=1566 n=1511 n=1371
887 (56.6%) 207 (13.7%) 80 (5.8%) 4%*
13.5 mg [7,10] n=1531 n=1475 n=1329
903 (59.0%) 249 (16.9%) 118 (8.9%) 6%*
p-values
52 mg vs. 19.5 mg b.001 b.001 .32
52 mg vs. 13.5 mg b.0001 b.0001 b.0001
19.5 mg vs. 13.5 mg .19 .02 .003
D. Irregular bleeding rates
52 mg [8] n=1700 n=1621 n=1448 n=1178
648 (38.1%) 220 (13.6)% 89 (6.1%) 52 (4.4%)
19.5 mg [4,9] n=1566 n=1511 n=1371
665 (42.5%) 377 (25.0%) 226 (16.5%) 14%⁎
13.5 mg [7,10] n=1531 n=1475 n=1329
643 (42.0%) 415 (28.1%) 300 (22.6%) 20%⁎
p-values
52 mg vs. 19.5 mg .01 b.0001 b.0001
52 mg vs. 13.5 mg .03 b.0001 b.0001
19.5 mg vs. 13.5 mg .80 .051 b.0001
See Table 1 for deﬁnitions of bleeding patterns.
IUS = Intrauterine System.
⁎ Data only available from years 1 and 3; year 2 estimated by interpolation so number is not presented and statistical testing at end of year 2 not calculated.
130 L.M. Goldthwaite, M.D. Creinin / Contraception 100 (2019) 128–131such a trial has not been performed. This information can be helpful for
clinicians when providing counseling to women about what patterns to
expect aswell as how to understand differences between the various le-
vonorgestrel IUS products. Women who are interested in maximizing
the likelihood of favorable bleeding should consider a levonorgestrel
52 mg IUS over the lower dose alternatives.
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A. Amenorrhea rates over 3 years 
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B. Infrequent bleeding rates over 2 years. 
 
  
0%
5%
10%
15%
20%
25%
30%
35%
1st 90
Days
2nd 90
Days
End of
year 1
End of
year 2
P
ro
p
o
rt
in
 o
f 
W
o
m
e
n
 R
e
p
o
rg
in
g 
In
fr
e
q
u
e
n
t 
B
le
e
d
in
g 
LNG 52 mg
LNG 19.5 mg
LNG 13.5 mg
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Goldthwaite, L  19 
 
C. Frequent bleeding rates over 2 years. 
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D. Prolonged bleeding rates over 2 years. 
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E. Irregular bleeding rates over 2 years. 
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